Related references
Note: Only part of the references are listed.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
G. Cavaletti et al.
ANNALS OF ONCOLOGY (2013)
Clinical pattern and associations of oxaliplatin acute neurotoxicity
Andreas A. Argyriou et al.
CANCER (2013)
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients
A. A. Argyriou et al.
ANNALS OF ONCOLOGY (2012)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients
Hong-Hee Won et al.
CANCER (2012)
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Andreas A. Argyriou et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Novel Insights into the Pathomechanisms of Skeletal Muscle Channelopathies
James A. Burge et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
Wolfgang Grisold et al.
NEURO-ONCOLOGY (2012)
Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current
Ruth Sittl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
Guido Cavaletti et al.
LANCET ONCOLOGY (2011)
Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?
A. G. Antonacopoulou et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Genome-wide association study of PR interval
Arne Pfeufer et al.
NATURE GENETICS (2010)
Pain perception is altered by a nucleotide polymorphism in SCN9A
Frank Reimann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy
Susanna B. Park et al.
BRAIN (2009)
Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity
Susanna B. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A review on oxaliplatin-induced peripheral nerve damage
Andreas A. Argyriou et al.
CANCER TREATMENT REVIEWS (2008)
Oxaliplatin-induced neurotoxicity and the development of neuropathy
AV Krishnan et al.
MUSCLE & NERVE (2005)
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
HP Kalofonos et al.
ANNALS OF ONCOLOGY (2005)
XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
J Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
International Union of Pharmacology. XXXIX. Compendium of voltage-gated ion channels: Sodium channels
WA Catterall et al.
PHARMACOLOGICAL REVIEWS (2003)
Overview of the voltage-gated sodium channel family
FH Yu et al.
GENOME BIOLOGY (2003)
Active intestinal chloride secretion in human carriers of cystic fibrosis mutations:: An evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion
C Högenauer et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels
WA Catterall
NEURON (2000)
Share Paper
